Response of MCF7 human breast cancer to Tamoxifen: Evaluation by the three-time-point, contrast-enhanced magnetic resonance imaging method

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2299-2304

  Furman Haran, Edna ^a   Grobgeld, Dov ^a   Margalit, Raanan ^a   Degani, Hadassa ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; ESTRADIOL; GADOLINIUM PENTETATE; TAMOXIFEN;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CELL STRAIN MCF 7; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING;

BREAST NEOPLASMS; CAPILLARY PERMEABILITY; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0031784409     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Folkman, J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res. Treat., 36: 109-118, 1995.
2. Weidner, N., and Folkman, J. Tumor vascularity as a prognostic factor in cancer. Important Adv. Oncol., 167-190, 1996.
3. Wahl, R. L., Zasadny, K., Helvie, M., Hutchins, G. D., Weber, B., and Cody, R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J. Clin. Oncol., 11: 2101-2111, 1993.
4. Jansson, T., Westlin, J. E., Ahlstrom, H., Lilja, A., Langstrom, B., and Bergh, J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J. Clin. Oncol., 13: 1470-1477, 1995.
5. Kedar, R. P., Cosgrove, D. O., Smith, I. E., Mansi, J. L., and Bamber, J. C. Breast carcinoma: measurement of tumor response to primary medical therapy with color doppler flow imaging. Radiology, 190: 825-830, 1994.
6. Abraham, D. C., Jones, R. C., Jones, S. E., Cheek, J. H., Peters G. N., Knox, S. M., Grant, M. D., Hampe, D. W., Savino, D. A., and Harms, S. E. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer (Phila.), 78: 91-100, 1996.
7. Rieber, A., Zeitler, H., Rosenthal, H., Gorich, J., Kreienberg, R., Brambs, H. J., and Tomczak, R. MRI of breast cancer: influence of chemotherapy on sensitivity. Br. J. Radiol., 70: 452-458, 1997.
8. Frouge, C., Guinebretiere, J-M., Contesso, G., Paola, R. D., and Blery, M. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis. Invest. Radiol., 29: 1043-1049, 1994.
9. Kelcz, F., Santyr, G. E., Cron, G. O., and Mongin, S. J. Application of a quantitative model to differentiate benign from malignant breast lesions detected by dynamic, gadolinium-enhanced MRI. J. Magn. Reson. Imaging, 6: 743-752, 1996.
10. Larsson, H. B. W., Stubgaard, M., Frederiksen, J. L., Jensen, M., Henriksen, O., and Paulson, O. B. Quantification of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn. Reson. Med., 16: 117-131, 1990.
11. Brix, G., Semmler, W., Port, R., Schad, L. R., Layer, G., and Lorenz, W. J. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J. Comput. Assisted Tomogr., 15: 621-628, 1991.
12. Tofts, P. S., and Kermode, A. G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn. Reson. Med., 17: 357-367, 1991.
13. Tofts, P. S., Berkowitz, B., and Schnall, M. D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn. Reson. Med., 33: 564-568, 1995.
14. Hamberg, L. M., Kristjansen, P. E. G., Hunter, G. J., Wolf, G. L., and Jain, R. K. Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05-μ1 resolution. Cancer Res., 54: 6032-6036, 1994.
15. Furman-Haran, E., Grobgeld, D., and Degani, H. Dynamic contrast enhanced imaging and analysis at high spatial resolutton of MCF7 human breast tumors. J. Magn. Reson., 128: 161-171, 1997.
16. Furman-Haran, E., Margalit, R., Grobgeld, D., and Degani, H. Dynamic contrast enhanced magnetic resonance imaging reveals stress induced angiogenesis in MCF7 human breast cancer. Proc. Natl. Acad. Sci. USA, 93: 6247-6251, 1996.
17. Degani, H., Gusis, V., Weinstein, D., Fields, S., and Strano, S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat. Med., 3: 780-782, 1997.
18. Haran, E. F., Maretzek, A. F., Goldberg, I., Horowitz, A., and Degani, H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res., 54: 5511-5514, 1994.
19. Knopp, M. V., Brix, G., Junkermann, H. J., and Sinn, H. P. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn. Reson. Imaging Clin. N. Am., 2: 633-658, 1994.
20. Evans, S. M., Koch, C. J., Laughlin, K. M., Jenkins, W. T., Van Winkle, T., and Wilson, D. F. Tamoxifen induces hypoxia in MCF7 xenografts. Cancer Res., 57: 5155-5161, 1997.
21. Gagliardi, A., and Collins, D. C. Inhibition of angiogenesis by antiestrogens. Cancer Res., 53: 533-535, 1993.
22. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
23. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Sender, D. R., and Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 53: 4727-4735, 1993.